Thymoglobulin IV Injection 25 mg/10 ml

Thymoglobulin IV Injection 25 mg/10 ml Uses, Dosage, Side Effects, Food Interaction and all others data.

Single-use 10 ml vial containing 25 mg of anti-thymocyte globulin (rabbit) lyophilized, sterile powder.The mechanism of action by which polyclonal antilymphocyte preparations suppress immune responses is not fully understood. Possible mechanisms by which Thymoglobulin IV Injection 25 mg/10 ml may induce immunosuppression in vivo include: T-cell clearance from the circulation and modulation of T-cell activation, homing, and cytotoxic activities. Thymoglobulin IV Injection 25 mg/10 ml includes antibodies against T-cell markers such as CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, HLA-DR, HLA Class I heavy chains, and ß2 micro-globulin. In vitro, Thymoglobulin IV Injection 25 mg/10 ml (concentrations >0.1 mg/mL) mediates T-cell suppressive effects via inhibition of proliferative responses to several mitogens. In patients, T-cell depletion is usually observed within a day after initiating Thymoglobulin IV Injection 25 mg/10 ml therapy. Thymoglobulin IV Injection 25 mg/10 ml has not been shown to be effective for treating antibody-mediated (humoral) rejections.

Thymoglobulin IV Injection 25 mg/10 ml
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Thymoglobulin IV Injection 25 mg/10 ml
Generic	Anti-Thymocyte Globulin
Weight	25 mg/10 ml
Type	IV Injection
Therapeutic Class	Vaccines, Anti-sera & Immunoglobulin
Manufacturer	Synovia Pharma PLC.
Available Country	Bangladesh
Last Updated:	October 19, 2023 at 6:27 am

Uses

Thymoglobulin IV Injection 25 mg/10 ml is an immunoglobulin G used for the prophylaxis and treatment of acute rejection in patients receiving a kidney transplant. Use in conjunction with concomitant immunosuppression.
Pediatric Use: The safety and effectiveness of Thymoglobulin IV Injection 25 mg/10 ml in pediatric patients have not been established in controlled trials. However, based on limited European studies and U.S. compassionate use, the dose, efficacy, and adverse reaction profile are not thought to be different than for adults.

Dosage

Thymoglobulin IV Injection 25 mg/10 ml dosage

The first dose should be infused over at least 6 hours; doses on subsequent days should be infused over at least 4 hours.

Premedication with corticosteroids, acetaminophen, and/or an antihistamine prior to each infusion is recommended.

The Thymoglobulin IV Injection 25 mg/10 ml dose should be reduced by one half if the white blood cell (WBC) count is between 2,000 and 3,000 cells/mm3 or if the platelet count is between 50,000 and 75,000 cells/mm3. Stopping Thymoglobulin IV Injection 25 mg/10 ml treatment should be considered if the WBC count falls below 2,000 cells/mm3 or if the platelet count falls below 50,000 cells/mm3

Prophylaxis of acute rejection: 1.5 mg/kg of body weight administered daily for 4 to 7 days
Treatment of acute rejection: 1.5 mg/kg of body weight administered daily for 7 to 14 days

Side Effects

The most common adverse reactions and laboratory abnormalities (incidence>5% higher than comparator) are urinary tract infection, abdominal pain, hypertension, nausea, shortness of breath, fever, headache, anxiety, chills, increased potassium levels in the blood, low counts of platelets and white blood cells

Precaution

Thymoglobulin IV Injection 25 mg/10 ml should only be used by physicians experienced in immunosuppressant therapy in transplantation.

Immune-mediated reactions: Thymoglobulin IV Injection 25 mg/10 ml infusion could result in an anaphylactic reaction.

Infusion-associated reactions: Close compliance with the recommended infusion time may reduce the incidence and severity of infusion-associated reactions.

Hematologic effects: low counts of platelets and white blood cells have been identified and are reversible following dose adjustments. Monitor total white blood cell and platelet counts.

Infection: Infections and reactivation of infections have been reported. Monitor patients and administer anti-infective prophylaxis.

Malignancy: Incidence of malignancies may increase.

Immunization with attenuated live vaccines is not recommended for patients who have recently received THYMOGLOBULIN. THYMOGLOBULIN may interfere with rabbit antibody–based immunoassays and with cross-match or panel-reactive antibody cytotoxicity assays.

Interaction

No drug interaction studies have been performed.

Pregnancy & Breastfeeding use

Animal reproduction studies have not been conducted with Thymoglobulin IV Injection 25 mg/10 ml. It is also not known whether Thymoglobulin IV Injection 25 mg/10 ml can cause fetal harm. Thymoglobulin IV Injection 25 mg/10 ml should be given to a pregnant woman only if the benefit outweighs the risk.

Thymoglobulin IV Injection 25 mg/10 ml has not been studied in nursing women. It is not known whether this drug is excreted in human milk. Because other immunoglobulins are excreted in human milk, breastfeeding should be discontinued during Thymoglobulin IV Injection 25 mg/10 ml therapy.

Contraindication

Allergy or anaphylactic reaction to rabbit proteins or to any product excipients, or active acute or chronic infections which contraindicate any additional immunosuppression